Connection

Robert Harrington to Platelet Aggregation Inhibitors

Back to Details
This is a "connection" page, showing publications Robert Harrington has written about Platelet Aggregation Inhibitors.
Robert Harrington
Connection Strength
15.001
Platelet Aggregation Inhibitors
  1. Management of Antithrombotic Therapy after Acute Coronary Syndromes. N Engl J Med. 2021 Feb 04; 384(5):452-460.
    View in: PubMed
    Score: 0.615
  2. Bleeding and Mortality With Dual Antiplatelet Therapy: The Rashomon Effect. J Am Coll Cardiol. 2017 04 25; 69(16):2023-2025.
    View in: PubMed
    Score: 0.473
  3. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC Cardiovasc Interv. 2015 Mar; 8(3):424-433.
    View in: PubMed
    Score: 0.407
  4. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). Am J Cardiol. 2015 May 15; 115(10):1325-32.
    View in: PubMed
    Score: 0.407
  5. Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. Int J Cardiol. 2014 Jan 01; 170(3):e59-62.
    View in: PubMed
    Score: 0.373
  6. Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. Eur Heart J Acute Cardiovasc Care. 2013 Sep; 2(3):246-55.
    View in: PubMed
    Score: 0.368
  7. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. Circ Cardiovasc Qual Outcomes. 2011 Jul; 4(4):448-58.
    View in: PubMed
    Score: 0.316
  8. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009 Dec 10; 361(24):2318-29.
    View in: PubMed
    Score: 0.284
  9. A new generation of antiplatelet agents. Curr Opin Cardiol. 2009 Jul; 24(4):307-12.
    View in: PubMed
    Score: 0.275
  10. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):670S-707S.
    View in: PubMed
    Score: 0.255
  11. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):708S-775S.
    View in: PubMed
    Score: 0.255
  12. Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials. J Interv Cardiol. 2007 Oct; 20(5):299-306.
    View in: PubMed
    Score: 0.244
  13. Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. Expert Rev Cardiovasc Ther. 2007 May; 5(3):401-12.
    View in: PubMed
    Score: 0.237
  14. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med. 2006 Apr 10; 166(7):806-11.
    View in: PubMed
    Score: 0.220
  15. Platelet inhibitor therapy for patients with cardiovascular disease: looking toward the future. Curr Hematol Rep. 2005 Sep; 4(5):397-404.
    View in: PubMed
    Score: 0.211
  16. Interventional cardiovascular pharmacotherapy: current issues. Am J Cardiovasc Drugs. 2005; 5(2):93-102.
    View in: PubMed
    Score: 0.202
  17. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thromb Haemost. 2004 Dec; 92(6):1182-93.
    View in: PubMed
    Score: 0.200
  18. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes. Semin Thromb Hemost. 2004 Dec; 30(6):639-47.
    View in: PubMed
    Score: 0.200
  19. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J. 2004 Mar; 147(3):457-62.
    View in: PubMed
    Score: 0.190
  20. Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. Am J Med. 2004 Jan 15; 116(2):119-29.
    View in: PubMed
    Score: 0.189
  21. Cardiology patient page. Antiplatelet therapy. Circulation. 2003 Aug 19; 108(7):e45-7.
    View in: PubMed
    Score: 0.183
  22. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation. 2002 Sep 17; 106(12):1470-6.
    View in: PubMed
    Score: 0.172
  23. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2002 Jan 22; 105(3):322-7.
    View in: PubMed
    Score: 0.164
  24. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. 2021 05 27; 384(21):1981-1990.
    View in: PubMed
    Score: 0.157
  25. Antithrombotic Therapy after Acute Coronary Syndromes. Reply. N Engl J Med. 2021 05 13; 384(19):1873-1874.
    View in: PubMed
    Score: 0.157
  26. Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. J Am Coll Cardiol. 2020 07 14; 76(2):162-171.
    View in: PubMed
    Score: 0.148
  27. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019 Oct 03; 381(14):1309-1320.
    View in: PubMed
    Score: 0.139
  28. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019 Sep 28; 394(10204):1169-1180.
    View in: PubMed
    Score: 0.139
  29. Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 08; 12(8):e007604.
    View in: PubMed
    Score: 0.139
  30. Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 07; 12(7):e007342.
    View in: PubMed
    Score: 0.138
  31. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clin Cardiol. 2019 May; 42(5):498-505.
    View in: PubMed
    Score: 0.135
  32. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment. Circ Cardiovasc Interv. 2019 03; 12(3):e007445.
    View in: PubMed
    Score: 0.134
  33. Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. J Am Heart Assoc. 2018 12 18; 7(24):e009609.
    View in: PubMed
    Score: 0.133
  34. Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. Int J Cardiol. 2019 Mar 01; 278:217-222.
    View in: PubMed
    Score: 0.132
  35. Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. Catheter Cardiovasc Interv. 2018 11 01; 92(5):E348-E355.
    View in: PubMed
    Score: 0.127
  36. Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circ Cardiovasc Interv. 2018 04; 11(4):e005635.
    View in: PubMed
    Score: 0.126
  37. Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. Int J Cardiol. 2018 Jan 01; 250:49-55.
    View in: PubMed
    Score: 0.122
  38. Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX. Circ Cardiovasc Interv. 2017 Aug; 10(8).
    View in: PubMed
    Score: 0.121
  39. Use of Antiplatelet Therapy/DAPT for?Post-PCI Patients Undergoing Noncardiac Surgery. J Am Coll Cardiol. 2017 Apr 11; 69(14):1861-1870.
    View in: PubMed
    Score: 0.118
  40. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017 Mar 14; 38(11):804-810.
    View in: PubMed
    Score: 0.117
  41. Cangrelor With and Without Glycoprotein?IIb/IIIa Inhibitors in?Patients?Undergoing Percutaneous?Coronary Intervention. J Am Coll Cardiol. 2017 Jan 17; 69(2):176-185.
    View in: PubMed
    Score: 0.116
  42. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2017 01; 10(1).
    View in: PubMed
    Score: 0.116
  43. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute?Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. JACC Cardiovasc Interv. 2016 09 26; 9(18):1905-13.
    View in: PubMed
    Score: 0.114
  44. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. Eur Heart J Acute Cardiovasc Care. 2017 Mar; 6(2):155-163.
    View in: PubMed
    Score: 0.114
  45. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Am Heart J. 2016 08; 178:176-84.
    View in: PubMed
    Score: 0.111
  46. Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Circ Cardiovasc Interv. 2016 06; 9(6).
    View in: PubMed
    Score: 0.111
  47. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2016 Jul; 177:1-8.
    View in: PubMed
    Score: 0.110
  48. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart. 2016 Apr; 102(8):617-25.
    View in: PubMed
    Score: 0.109
  49. Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. Circulation. 2016 Jan 19; 133(3):248-55.
    View in: PubMed
    Score: 0.108
  50. Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. Catheter Cardiovasc Interv. 2016 Aug; 88(2):163-73.
    View in: PubMed
    Score: 0.108
  51. Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. J Am Coll Cardiol. 2015 Feb 10; 65(5):465-76.
    View in: PubMed
    Score: 0.102
  52. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014 Aug 14; 35(31):2083-93.
    View in: PubMed
    Score: 0.096
  53. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. Eur Heart J Acute Cardiovasc Care. 2014 Sep; 3(3):246-56.
    View in: PubMed
    Score: 0.095
  54. Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Am J Cardiol. 2014 Mar 15; 113(6):936-44.
    View in: PubMed
    Score: 0.094
  55. Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. J Thromb Thrombolysis. 2013 Nov; 36(4):384-93.
    View in: PubMed
    Score: 0.093
  56. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013 Dec 14; 382(9909):1981-92.
    View in: PubMed
    Score: 0.092
  57. Platelet inhibition with cangrelor during PCI. N Engl J Med. 2013 07 25; 369(4):393-4.
    View in: PubMed
    Score: 0.091
  58. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. Am Heart J. 2013 Sep; 166(3):466-73.
    View in: PubMed
    Score: 0.091
  59. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv. 2013 Jul; 6(7):671-83.
    View in: PubMed
    Score: 0.091
  60. Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". Stroke. 2013 Aug; 44(8):e95-6.
    View in: PubMed
    Score: 0.091
  61. Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke. 2013 May; 44(5):1477-9.
    View in: PubMed
    Score: 0.089
  62. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA?CER) trial. Eur Heart J. 2013 Jun; 34(23):1723-31.
    View in: PubMed
    Score: 0.089
  63. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013 Apr 04; 368(14):1303-13.
    View in: PubMed
    Score: 0.089
  64. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. JACC Cardiovasc Interv. 2012 Sep; 5(9):927-35.
    View in: PubMed
    Score: 0.086
  65. Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. Int J Cardiol. 2013 Sep 10; 167(6):2580-7.
    View in: PubMed
    Score: 0.085
  66. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012 Jun; 5(3):336-46.
    View in: PubMed
    Score: 0.084
  67. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv. 2012 Jun; 5(3):347-56.
    View in: PubMed
    Score: 0.084
  68. Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. Circ Cardiovasc Qual Outcomes. 2012 Mar 01; 5(2):205-13.
    View in: PubMed
    Score: 0.083
  69. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012 Feb 28; 125(8):978-86.
    View in: PubMed
    Score: 0.082
  70. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011 Dec; 32(23):2933-44.
    View in: PubMed
    Score: 0.081
  71. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012 Jan 05; 366(1):20-33.
    View in: PubMed
    Score: 0.081
  72. Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. Am Heart J. 2011 Nov; 162(5):884-892.e1.
    View in: PubMed
    Score: 0.081
  73. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). Am J Cardiol. 2011 Dec 01; 108(11):1542-6.
    View in: PubMed
    Score: 0.080
  74. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J. 2011 Dec; 32(23):2945-53.
    View in: PubMed
    Score: 0.079
  75. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011 Aug 25; 365(8):699-708.
    View in: PubMed
    Score: 0.079
  76. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011 Jun 17; 342:d3527.
    View in: PubMed
    Score: 0.079
  77. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011 May 10; 57(19):1908-16.
    View in: PubMed
    Score: 0.078
  78. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation. 2011 Feb 22; 123(7):722-30.
    View in: PubMed
    Score: 0.077
  79. Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. Am Heart J. 2010 Dec; 160(6):1056-64, 1064.e2.
    View in: PubMed
    Score: 0.076
  80. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010 Nov 23; 122(21):2131-41.
    View in: PubMed
    Score: 0.076
  81. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010 Sep 14; 122(11):1056-67.
    View in: PubMed
    Score: 0.075
  82. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23; 375(9711):283-93.
    View in: PubMed
    Score: 0.071
  83. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009 Dec 10; 361(24):2330-41.
    View in: PubMed
    Score: 0.071
  84. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J. 2009 Dec; 158(6):998-1004.e1.
    View in: PubMed
    Score: 0.071
  85. Antithrombotics in acute coronary syndromes. J Am Coll Cardiol. 2009 Sep 08; 54(11):969-84.
    View in: PubMed
    Score: 0.070
  86. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10; 361(11):1045-57.
    View in: PubMed
    Score: 0.070
  87. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009 Jun 09; 119(22):2877-85.
    View in: PubMed
    Score: 0.068
  88. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009 May 21; 360(21):2176-90.
    View in: PubMed
    Score: 0.068
  89. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009 Mar 14; 373(9667):919-28.
    View in: PubMed
    Score: 0.067
  90. Clinical decisions. Management of stable coronary disease. N Engl J Med. 2007 Oct 25; 357(17):1762-6.
    View in: PubMed
    Score: 0.061
  91. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007 Nov 06; 50(19):1844-51.
    View in: PubMed
    Score: 0.061
  92. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. Catheter Cardiovasc Interv. 2007 Jul 01; 70(1):43-50.
    View in: PubMed
    Score: 0.060
  93. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Am J Cardiol. 2007 May 15; 99(10):1389-93.
    View in: PubMed
    Score: 0.059
  94. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007 Jan 10; 297(2):159-68.
    View in: PubMed
    Score: 0.058
  95. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J. 2006 Mar; 151(3):689.e1-689.e10.
    View in: PubMed
    Score: 0.055
  96. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006 Feb 21; 47(4):809-16.
    View in: PubMed
    Score: 0.054
  97. Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study". Circulation. 2005 Oct 25; 112(17):e282; author reply e283.
    View in: PubMed
    Score: 0.053
  98. Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. Am J Cardiol. 2005 Jun 15; 95(12):1404-8.
    View in: PubMed
    Score: 0.052
  99. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). Am J Cardiol. 2005 Mar 01; 95(5):611-4.
    View in: PubMed
    Score: 0.051
  100. Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Feb 18; 43(4):549-56.
    View in: PubMed
    Score: 0.047
  101. Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. Am Heart J. 2004 Jan; 147(1):84-90.
    View in: PubMed
    Score: 0.047
  102. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J. 2003 Oct; 146(4):628-34.
    View in: PubMed
    Score: 0.046
  103. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003 Jul 29; 108(4):399-406.
    View in: PubMed
    Score: 0.046
  104. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. J Am Coll Cardiol. 2003 Apr 16; 41(8):1251-60.
    View in: PubMed
    Score: 0.045
  105. Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. J Am Coll Cardiol. 2003 Feb 05; 41(3):371-80.
    View in: PubMed
    Score: 0.044
  106. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Am Heart J. 2002 Dec; 144(6):995-1002.
    View in: PubMed
    Score: 0.044
  107. Biomarker-Based Prediction of Recurrent?Ischemic Events in Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2022 11 01; 80(18):1735-1747.
    View in: PubMed
    Score: 0.043
  108. External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry. Int J Cardiol. 2023 Jan 01; 370:51-57.
    View in: PubMed
    Score: 0.043
  109. The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med. 2002 Jun 01; 112(8):647-58.
    View in: PubMed
    Score: 0.042
  110. Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCI. Am Heart J. 2022 07; 249:23-33.
    View in: PubMed
    Score: 0.042
  111. Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. Circ Cardiovasc Interv. 2022 Mar; 15(3):e011069.
    View in: PubMed
    Score: 0.041
  112. Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy). Cardiology. 2002; 98(4):195-201.
    View in: PubMed
    Score: 0.041
  113. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. Circ Cardiovasc Interv. 2022 01; 15(1):e010390.
    View in: PubMed
    Score: 0.041
  114. Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. Circ Cardiovasc Interv. 2021 12; 14(12):e011035.
    View in: PubMed
    Score: 0.041
  115. Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. JAMA Cardiol. 2020 05 01; 5(5):598-607.
    View in: PubMed
    Score: 0.036
  116. Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. Am Heart J. 2019 09; 215:106-113.
    View in: PubMed
    Score: 0.034
  117. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. Blood Cells Mol Dis. 2018 09; 72:37-43.
    View in: PubMed
    Score: 0.032
  118. Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. EuroIntervention. 2018 02 02; 13(15):e1841-e1849.
    View in: PubMed
    Score: 0.031
  119. Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). Am J Cardiol. 2017 Oct 01; 120(7):1043-1048.
    View in: PubMed
    Score: 0.030
  120. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. JAMA Cardiol. 2017 02 01; 2(2):127-135.
    View in: PubMed
    Score: 0.029
  121. Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. Int J Cardiol. 2017 Apr 01; 232:264-270.
    View in: PubMed
    Score: 0.029
  122. Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. Eur Heart J Acute Cardiovasc Care. 2018 Mar; 7(2):158-165.
    View in: PubMed
    Score: 0.028
  123. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circulation. 2016 Sep 06; 134(10):723-33.
    View in: PubMed
    Score: 0.028
  124. Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. J Am Coll Cardiol. 2016 May 10; 67(18):2135-2144.
    View in: PubMed
    Score: 0.028
  125. Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. Int J Cardiol. 2016 Jan 15; 203:708-13.
    View in: PubMed
    Score: 0.027
  126. Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention. 2015 Nov; 11(7):737-45.
    View in: PubMed
    Score: 0.027
  127. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. Eur Heart J. 2016 Apr 07; 37(14):1122-30.
    View in: PubMed
    Score: 0.026
  128. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. Am Heart J. 2014 Dec; 168(6):869-77.e1.
    View in: PubMed
    Score: 0.025
  129. Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. Am Heart J. 2013 Oct; 166(4):723-8.
    View in: PubMed
    Score: 0.023
  130. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013 Sep 03; 128(10):1055-65.
    View in: PubMed
    Score: 0.023
  131. Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. Am Heart J. 2013 Apr; 165(4):583-590.e1.
    View in: PubMed
    Score: 0.022
  132. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J. 2012 May; 163(5):768-776.e2.
    View in: PubMed
    Score: 0.021
  133. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation. 2012 Jan 24; 125(3):514-21.
    View in: PubMed
    Score: 0.020
  134. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011 Aug 02; 124(5):544-54.
    View in: PubMed
    Score: 0.020
  135. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J. 2010 Jul; 160(1):65-72.
    View in: PubMed
    Score: 0.018
  136. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv. 2009 Nov; 2(11):1083-91.
    View in: PubMed
    Score: 0.018
  137. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation. 2009 May 12; 119(18):2454-62.
    View in: PubMed
    Score: 0.017
  138. Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. Am Heart J. 2009 Apr; 157(4):716-23.
    View in: PubMed
    Score: 0.017
  139. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008 Feb; 155(2):369-74.
    View in: PubMed
    Score: 0.015
  140. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. Ann Thorac Surg. 2007 Mar; 83(3):993-1001.
    View in: PubMed
    Score: 0.015
  141. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med. 2006 Oct 09; 166(18):2027-34.
    View in: PubMed
    Score: 0.014
  142. Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. J Thromb Thrombolysis. 2006 Jun; 21(3):211-20.
    View in: PubMed
    Score: 0.014
  143. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004 Aug 21-27; 364(9435):675-84.
    View in: PubMed
    Score: 0.012
  144. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Can J Cardiol. 2004 Jun; 20(8):773-8.
    View in: PubMed
    Score: 0.012
  145. Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. Am Heart J. 2004 May; 147(5):847-52.
    View in: PubMed
    Score: 0.012
  146. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. J Am Coll Cardiol. 2004 Apr 07; 43(7):1170-6.
    View in: PubMed
    Score: 0.012
  147. Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. Am J Med. 2003 Dec 01; 115(8):613-9.
    View in: PubMed
    Score: 0.012
  148. Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol. 2003 Aug 01; 92(3):330-3.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.